Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients

dc.contributor.authorHan, Alice
dc.contributor.authorRodriguez, Tulio E.
dc.contributor.authorBeck, Eric T.
dc.contributor.authorRelich, Ryan F.
dc.contributor.authorUdeoji, Dioma U.
dc.contributor.authorPetrak, Robert
dc.contributor.authorChundi, Vishnu V.
dc.contributor.departmentPathology and Laboratory Medicine, School of Medicineen_US
dc.date.accessioned2021-03-09T21:23:12Z
dc.date.available2021-03-09T21:23:12Z
dc.date.issued2021-03
dc.description.abstractThe coronavirus disease 19 (COVID-19) pandemic has infected tens of millions across the world, but there is a significant gap in our understanding about COVID-19 in the hematopoietic stem transplant (HSCT) recipient population. Prolonged viral shedding is frequently observed with severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), but studies suggest viral loads decline 10 days after symptom onset. Current CDC guidance suggests that severely ill and immunocompromised hosts are no longer infectious after 20 days from symptom onset. Cycle threshold (Ct) values are inversely proportional to the viral load and are used to detect SARS-CoV-2 RNA concentration. Specimens with reverse transcriptase PCR (RT-PCR) Ct values > 33–34 have been associated with inability to culture virus, and have been used as a surrogate for diminished infectivity. We report two cases of allogeneic peripheral blood stem cell transplant (PBSCT) recipients who had prolonged durations of infectivity with SARSCov-2, based on culture positivity and persistently low Ct values for greater than 50 days.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationHan, A., Rodriguez, T. E., Beck, E. T., Relich, R. F., Udeoji, D. U., Petrak, R., & Chundi, V. V. (2021). Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients. Current Problems in Cancer: Case Reports, 3, 100057. https://doi.org/10.1016/j.cpccr.2021.100057en_US
dc.identifier.urihttps://hdl.handle.net/1805/25344
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.cpccr.2021.100057en_US
dc.relation.journalCurrent Problems in Cancer: Case Reportsen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0*
dc.sourcePublisheren_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectpersistent infectionen_US
dc.titlePersistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipientsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Han2021Persistent.pdf
Size:
457.7 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: